ORCHPHARMA.NS Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 13:00):

Stats
Šios dienos apimtis	63 966.00
Vidutinė apimtis	240 658
Rinkos kapitalizacija	55.00B
EPS	INR0 ( 2024-02-09 )
Kita pelno data	( INR0 ) 2024-05-07
Last Dividend	INR3.00 ( 2012-09-13 )
Next Dividend	INR0 ( N/A )
P/E	38.03
ATR14	INR0.974 (0.09%)

Tūris Koreliacija

Ilgas: -0.07 (neutral)

Trumpas: -0.87 (strong negative)

Signal:(45.897) Neutral

Orchid Pharma Limited Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Orchid Pharma Limited Koreliacija - Valiuta/Žaliavos

-0.20
( neutral )

-0.13
( neutral )

0.01
( neutral )

-0.40
( neutral )

-0.33
( neutral )

0.63
( weak )

Orchid Pharma Limited Finansinės ataskaitos

Annual	2022
Pajamos:	INR6.66B
Bruto pelnas:	INR2.81B (42.24 %)
EPS:	INR11.35

FY	2022
Pajamos:	INR6.66B
Bruto pelnas:	INR2.81B (42.24 %)
EPS:	INR11.35

FY	2022
Pajamos:	INR5.60B
Bruto pelnas:	INR2.33B (41.69 %)
EPS:	INR-0.350

FY	2021
Pajamos:	INR4.50B
Bruto pelnas:	INR2.10B (46.68 %)
EPS:	INR-28.55

Financial Reports:

No articles found.

Orchid Pharma Limited Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Orchid Pharma Limited Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 4.51 - low (49.98%) | Divividend Growth Potential Score: 2.49 - No dividend growth expected in the near future

Information

First Dividend	INR2.67	2002-07-16
Last Dividend	INR3.00	2012-09-13
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	11	--
Total Paid Out	INR36.67	--
Avg. Dividend % Per Year	0.00%	--
Score	1.66	--
Div. Sustainability Score	4.51
Div.Growth Potential Score	2.49
Div. Directional Score	3.50	--

Next Divdend (Est)
(2024-06-17)

INR0 Estimate 0.00 %

Dividend Stability

0.03 Very Bad

Dividend Score

1.66

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2002	INR0	0.00%
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR0	0.00%
2019	INR0	0.00%
2020	INR0	0.00%
2021	INR0	0.00%
2022	INR0	0.00%
2023	INR0	0.00%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SUNDARMHLD.NS	Dividend Junior	2023-07-03	Annually	7	1.35%
NATIONALUM.NS	Dividend Knight	2023-09-15	Semi-Annually	26	4.12%
HLEGLAS.NS	Dividend Junior	2023-09-21	Annually	4	0.19%
CANTABIL.NS	Dividend Junior	2023-09-15	Annually	5	0.63%
RITES.NS	Dividend Knight	2023-09-08	Quarterly	7	3.95%
LAMBODHARA.NS	Dividend Junior	2023-09-14	Annually	10	0.87%
FORCEMOT.NS	Dividend Junior	2023-09-21	Annually	6	0.45%
APLAPOLLO.NS	Ex Dividend Junior	2023-09-01	Sporadic	13	0.07%
TATVA.NS	Dividend Junior	2023-09-08	Annually	3	0.04%
NUCLEUS.NS	Dividend Junior	2023-07-07	Annually	22	1.41%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.145	1.500	7.10	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.131	1.500	9.65	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	5.21	1.000	9.18	9.18	[3 - 30]
operatingCashFlowPerShareTTM	12.63	2.00	5.79	10.00	[0 - 30]
freeCashFlowPerShareTTM	12.63	2.00	3.69	7.37	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.415	1.000	6.42	6.42	[0.2 - 0.8]
operatingProfitMarginTTM	0.131	1.000	9.38	9.38	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				4.51

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	46.70	1.000	5.38	0	[1 - 100]
returnOnEquityTTM	0.131	2.50	9.78	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	12.63	2.00	5.79	7.37	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	12.63	2.00	5.79	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-1.243	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0789	1.000	-0.528	0	[0.1 - 0.5]
Total Score				2.49

Orchid Pharma Limited

Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins, veterinary products, and non-antibiotics. The company's multi-therapeutic presence in anti-infectives, anti-inflammatory, central nervous system, cardiovascular segment, nutraceuticals, and other oral and sterile products, as well as offers new drug discovery systems and pharmaceutical research and development services. It also exports its products to approximately 40 countries internationally. In addition, the company provides liaising support to customers in regulatory, pharma covigilance, testing and release, retention of samples, service providers, and business development. The company was formerly known as Orchid Chemicals & Pharmaceuticals Limited and changed its name to Orchid Pharma Limited in October 2015. Orchid Pharma Limited was incorporated in 1992 and is headquartered in Chennai, India. Orchid Pharma Limited is a subsidiary of Dhanuka Laboratories Limited.